Julio Hajdenberg

Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT₃ receptor antagonist

Peter D. Eisenberg, Jazmin Figueroa‐Vadillo, Rosalio Zamora et al. · Cancer · 2003 · 404 citations · Full text

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

Walter M. Stadler, Robert A. Figlin, David F. McDermott et al. · Cancer · 2010 · 253 citations

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non–Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma

John P. Leonard, Kathryn S. Kolibaba, James A. Reeves et al. · Journal of Clinical Oncology · 2017 · 187 citations

Sacituzumab Govitecan, a Novel Antibody–Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma

Bishoy M. Faltas, David M. Goldenberg, Allyson J. Ocean et al. · Clinical Genitourinary Cancer · 2015 · 102 citations · Full text

Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.

Thomas Grote, Julio Hajdenberg, Alan Cartmell et al. · PubMed · 2006 · 91 citations

Emetogenic Chemotherapy, Receptor Antagonist, Pharmacotherapy +16